Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal

Core Insights - Silo Pharma, Inc. announced the publication of preclinical research for its Alzheimer's disease therapeutic, SPC-14, in a leading scientific journal, Alzheimer's Research & Therapy [1][2] - The study indicates that the combination of (R,S)-ketamine and prucalopride is a novel therapeutic strategy for treating cognitive decline in Alzheimer's disease [2] - SPC-14 has shown promising results in improving cognitive decline in preclinical models, suggesting its potential as a therapeutic option for Alzheimer's disease [3] Company Overview - Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on addressing underserved conditions, including Alzheimer's disease [5] - The company has developed SPC-14 under a sponsored research agreement with Columbia University and has an exclusive global license to further develop and commercialize the product [4] - Silo's portfolio includes other innovative programs targeting conditions such as PTSD and chronic pain, indicating a broad therapeutic focus [5] Market Potential - The Alzheimer's disease treatment market is projected to grow to $30.8 billion by 2033, with a compound annual growth rate (CAGR) of 18.8% [4][7] - SPC-14 targets glutamate receptor NMDAR and serotonin type 4 receptor 5HT4, addressing cognitive and neuropsychiatric symptoms associated with Alzheimer's disease [4]